Clinical bottom line
Pediatric sudden sensorineural hearing loss (SSNHL) remains a diagnostic and therapeutic challenge due to its rarity and heterogeneous etiology. Recent advances emphasize early comprehensive audiologic and radiologic evaluation, including MRI, to identify underlying causes such as viral, vascular, or perilymphatic fistula origins. Corticosteroids remain the mainstay of treatment, with emerging evidence supporting adjunctive hyperbaric oxygen therapy (HBOT) in select cases. However, standardized pediatric-specific protocols are lacking, and practice variability persists. Multidisciplinary approaches and timely intervention are critical to optimize hearing recovery in this vulnerable population (Hanson et al., 2026; Luu et al., 2023).
What the evidence shows
Hanson et al. (2026) provide a comprehensive overview of pediatric SSNHL, highlighting that while idiopathic cases predominate, identifiable etiologies include viral infections, vascular insults, and inner ear anomalies. Early audiometric assessment combined with MRI, as detailed by Herrera et al. (2024), improves detection of retrocochlear pathology and vascular abnormalities, guiding management.
Lambert et al. (2018) underscore corticosteroids as first-line therapy, with systemic and intratympanic routes showing comparable efficacy. However, pediatric dosing and duration require further study.
Luu et al. (2023) document significant variability in clinical practice, reflecting uncertainty in diagnostic workup and treatment, including inconsistent use of imaging and adjunctive therapies.
Shaheen et al. (2024) report promising results for HBOT as an adjunct to steroids, potentially enhancing oxygen delivery to the cochlea and improving outcomes, though pediatric-specific data remain limited.
Rodríguez Izquierdo et al. (2024) advocate for a tailored diagnostic approach incorporating clinical history, audiometry, imaging, and laboratory tests to refine etiology and prognosis.
Dedhia et al. (2016) provide case series data supporting early intervention correlating with better hearing recovery, emphasizing the need for prompt referral and treatment initiation.
Caveats and uncertainty
High-quality randomized controlled trials in pediatric SSNHL are scarce, limiting evidence strength.
Etiologic heterogeneity complicates standardized treatment algorithms.
MRI accessibility and sedation requirements pose practical challenges in young children.
Long-term hearing outcomes and neurodevelopmental impacts require further investigation.
The role and timing of HBOT need validation in pediatric cohorts.
How this may change practice
Clinicians should prioritize early audiologic evaluation and MRI imaging in pediatric SSNHL to identify treatable causes.
Standardized corticosteroid protocols adapted for children should be developed and implemented.
Consideration of HBOT as adjunctive therapy may be appropriate in refractory cases, pending further evidence.
Multidisciplinary coordination among otolaryngologists, audiologists, radiologists, and pediatricians is essential.
Enhanced awareness and education on pediatric SSNHL can reduce diagnostic delays and improve outcomes.